Sun, Mar 1, 2015, 3:25 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

oldfolks95610 10 posts  |  Last Activity: Feb 26, 2015 4:55 PM Member since: Dec 27, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Other possible targets

    by oldfolks95610 Feb 26, 2015 4:51 PM
    oldfolks95610 oldfolks95610 Feb 26, 2015 4:55 PM Flag

    ratio’s in a 2008 study suggested that neuron damage had indeed occurred in the hippocampus. A meta-analysis of magnetic resonance spectroscopy findings concluded significant hippocampal NAA reductions are present in FM. A recent study linked cognitive problems in fibromyalgia with hippocampal dysfunction.

    hippocampus fibromyalgia
    Earlier findings suggested something had gone wrong with the hippocampus

    The researchers inability to find correlations between levels of pain and sleep efficiency, however, suggested that the smaller hippocampi in the FM patients was not significantly contributing to their symptoms. (Despite the fact that the hippocampus plays a major role in cognition including short-term memory and cognition, they did not examine cognition. )

    The fact that hippocampal atrophy was not associated with increased pain, symptom severity or decreased sleep efficiency suggested the atrophy found may have been secondary; i.e. it was the result of having FM rather than being the cause of it. More extensive symptom tests, might, however have found an association and that could change.

    Whatever the symptom tests showed, the hippocampus is a major organ in the brain – not exactly something you want to have atrophy a bit. When the authors asked what could be causing the reduced hippocampal grey matter one of the usual suspects in FM showed up: glutamate/GABA imbalance or nervous system burnout.

  • oldfolks95610 by oldfolks95610 Feb 26, 2015 4:51 PM Flag

    New study.

    2015 Jan 30;8:47-52. doi: 10.2147/JPR.S71959. eCollection 2015. Fibromyalgia patients have reduced hippocampal volume compared with healthy controls.McCrae CS1, O’Shea AM1, Boissoneault J2, Vatthauer KE1, Robinson ME3, Staud R4, Perlstein WM5, Craggs JG1.

    This Florida group was looking to add another brain region to the list: the hippocampus, a part of the limbic system that plays an important role in short-term memory (remember that?), long-term memory (generally thought to be intact) and “spatial navigation”. The hippocampus isn’t directly involved in the production of pain but a breakdown in hippocampal functioning could lead to a “feed-forward” process that ends up disrupting the limbic system and the pain networks in the brain.

    Hippocampal problems could then conceivably result in discomfort, severe pain, anxiety and perhaps even the mysterious and disturbing allodynia that some people with FM experience.

    Some evidence of hippocampal atrophy exists in FM but this was the first time depression was controlled for in a study. Because hippocampal atrophy is also present in depression and because depression is fairly common in fibromyalgia, the atrophy could have been due to depression.

    In this nice-sized (for a brain imaging study) 22 healthy controls and 40 fibromyalgia patients got into an MRI machine and had their hippocampal volumes analyzed. Rates of depression, pain disability, sleep efficiency were assessed as well.


    You can another brain abnormality to the growing list. The hippocampus is made up of two hemispheres and hippocampal grey matter volumes were significantly reduced in both of them (p

  • Reply to

    Why I am in

    by captainblud Feb 20, 2015 9:48 AM
    oldfolks95610 oldfolks95610 Feb 20, 2015 1:23 PM Flag

    Good, nice little calculation. We could also add a factor for being a first mover and irrational buying and add some to the pot.

  • Reply to

    Bleeding money

    by garroty Feb 10, 2015 6:29 PM
    oldfolks95610 oldfolks95610 Feb 11, 2015 12:41 PM Flag

    Don't we have a trial for that?

  • New Grandbaby Connor 7 lbs. 11 ounces doing great. Entire account up over 20% in Dec. with one day left before I can take profits to push taxes into next year. Not a bad month.
    Happy New Year.
    Old fat and happy.

  • Reply to

    Today's price action was a scam

    by o0o0o77 Dec 12, 2014 10:22 PM
    oldfolks95610 oldfolks95610 Dec 13, 2014 2:50 PM Flag

    I kept thinking the stock price was subject to error on Friday. Just terribly odd, not enough volume for anyone to make millions maybe a few G's

  • Reply to

    JUNO IPO another like KITE maybe better

    by oldfolks95610 Dec 9, 2014 9:41 PM
    oldfolks95610 oldfolks95610 Dec 9, 2014 10:03 PM Flag

    SAN FRANCISCO (TheStreet) -- Treatment with re-engineered immune cells designed to kill leukemia has led to complete remissions in more than 90% of a small group of children and young adults with an aggressive form of the disease enrolled in an ongoing, early-stage study.

    More than two-thirds of the patients remain cancer free six months following treatment and 75% of patients are still alive, said researchers from the University of Pennsylvania and Novartis (NVS) , speaking during a media briefing Saturday at the American Society of Hematology (ASH) annual meeting taking place here.

    This new form of cancer immunotherapy, which scientists refer to as CAR-T for the receptor added to killer T cells in the lab, promises to radically change the way certain blood cancers are treated. CAR-T therapies are also generating tremendous commercial and investor interest. The UPenn-Novartis joint venture is competing with Juno Therapeutics, a red-hot private company expected to price a $150 million initial public offering early next year.

    Other CAR-T companies include Kite Therapeutics (KITE) and a joint venture between Celgene (CELG) and Bluebird Bio (BLUE) .

    The study updated today enrolled 39 children and young adults with relapsed, treatment-resistant acute lymphocytic leukemia (ALL). After the experimental UPenn-Novartis treatment known as CTL019 was given, 36 of 39 patients, or 92%, went into complete remission, meaning there was no evidence of disease in their bodies. Six months after receiving CTL019, 70% of patients remain cancer free, and only five patients ha

  • Seattle-based Juno plans to raise $153 million in its initial public offering, selling 9.3 million shares at a price of 15 to 18. At the midpoint of the proposed range, Juno would have a market value of roughly $1.5 billion. That would make it the largest biotech IPO of 2014 by market cap, at the time of its IPO, according to IPO ETF manager Renaissance Capital.

    Meanwhile, Kite Pharma (NASDAQ:KITE), which is also developing immunotherapies for the treatment of cancer, rose 17% to close at 51.56 on the stock market today. Kite Pharma raised $128 million in its June 20 IPO, offering 7.5 million shares at 17. But with its run-up, Kite's market cap now is flying just under $2 billion

    If we have a good day this one may explode. It certainly got a lot of attention from the venture capitalist.

  • Reply to

    Awesome!!!! BLUE Skies

    by oldfolks95610 Dec 8, 2014 11:12 PM
    oldfolks95610 oldfolks95610 Dec 9, 2014 2:57 PM Flag

    This is amazing, all my engineering stocks following BLUE. Sold the KITE at 50 and it went up another 3. Too good almost now a little anxious. KITE is on the cusp of an offering and I will get back in on that if t happens. CLDN, QURE,SGMO,ISIS,SRPT and I guess some I don't have.

  • oldfolks95610 by oldfolks95610 Dec 8, 2014 11:12 PM Flag

    ISIS and BLUE both up 4 dollars and change today from my basket of Genetic engineered bios. I only have 200 of each but Blue up 20.00 after hours on trial results!! Nice wish I had more but my basket has about 2k shares in several engineered stocks and most are up well so I can't complain. KITE,QURE,CLDN,SGMO and others.
    Merry Christmas, Old

3.08-0.07(-2.22%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Aruba Networks, Inc.
NASDAQFri, Feb 27, 2015 4:00 PM EST
Flamel Technologies SA
NASDAQFri, Feb 27, 2015 4:00 PM EST